CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals Breakthrough technology enables a family of chemicals, traditionally derived from petroleum, to be made renewably
CAMBRIDGE, Mass., March 14, 2012 /PRNewswire-iReach/ -- CELEXION LLC today announced the issuance of US Patent number 8,133,704 by the US Patent and Trademark Office entitled "Biological synthesis of difunctional alkanes from carbohydrate feedstocks." The patent was issued on March 13, 2012 and covers biological methods of converting renewable feedstocks into a variety of high-value chemicals with a total market value of over $10B.
"At CELEXION, we leverage the power of biological systems to make new, high performance products and to make everyday products more functional, affordable, and sustainable," said Dr. Brian M. Baynes, CEO of CELEXION and co-inventor of the technology. "The methods disclosed in this patent enable a variety of important bulk chemicals to be synthesized from renewable starting materials using biological catalysts. The efficiency of this approach makes our products not only sustainable, but also less expensive than their petroleum-derived equivalents."
Claims of the '704 patent include key biosynthetic steps from common metabolic intermediates and their uses in manufacturing a family of chemicals including adipic acid, caprolactam, hexamethylenediamine, pimelic acid, and caprolactone. These chemicals are key components in a wide variety of packaging, materials, polymers, and other industrial and consumer applications.
CELEXION LLC is a bioengineering company that develops powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. The company's technologies include the SECANT platform for engineering high performance protein products, a library of human antibodies for therapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value chemicals and materials from wastes and other inexpensive precursors, and a novel family of enzymes for manipulation of chromosome-sized DNA. CELEXION is headquartered in Cambridge, MA, USA. For further information, please visit our website at www.celexionbio.com.
CELEXION and SECANT are registered trademarks of Celexion LLC.
Media Contact: Celexion Business Development, Celexion LLC, +1-617-500-3011 x1, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE CELEXION LLC